Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
Returns on capital
Edesa Biotech, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-57.7%
avg -101.2%
ROIC
-63.5%
avg -113.4%
ROA
-53.1%
avg -75.7%
Analysis
ROA is currently the strongest return metric at -53.1% versus its period average of -75.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Pardeep Nijhawan FRCPC | Chief Executive Officer, Company Secretary & Director | USD 483.83K | 55 | — | — |
Michael J. Brooks | President | USD 450.21K | 47 | 291.48K | 3.28% |
Peter John Weiler | Chief Financial Officer | USD 310.56K | 57 | — | — |
Compensation is shown in the reported currency; data updated Jul 25, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 27, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$226,455.15
Sells
0
$0.00
Net Transaction Value
+$226,455.15
Net buying
Most Active
Nijhawan Pardeep
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Mar 5, 26Mar 5, 2026 | Nijhawan Pardeep Indirect | Buy | $39K$39,000.00 |
| Mar 4, 26Mar 4, 2026 | Nijhawan Pardeep Indirect | Buy | $42.6K$42,560.00 |
| Mar 3, 26Mar 3, 2026 | Nijhawan Pardeep Indirect | Buy | $36.3K$36,300.00 |
| Mar 2, 26Mar 2, 2026 | Nijhawan Pardeep Direct | Buy | $4K$4,000.00 |
| Mar 2, 26Mar 2, 2026 | Nijhawan Pardeep Indirect | Buy | $2.3K$2,279.60 |
| Feb 27, 26Feb 27, 2026 | Nijhawan Pardeep Indirect | Buy | $66.7K$66,696.00 |
| Feb 26, 26Feb 26, 2026 | Brooks Michael J Direct | Buy | $3.1K$3,140.00 |
| Feb 26, 26Feb 26, 2026 | Nijhawan Pardeep Direct | Buy | $32.5K$32,479.55 |
Summary
Insiders reported 8 buys worth $226,455.15 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $226,455.15. Nijhawan Pardeep was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Edesa Biotech, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about EDSA's management, answered from reported figures.
Who manages EDSA?
Edesa Biotech, Inc. (EDSA) lists 3 active executives. The top listed executive is Peter John Weiler, Chief Financial Officer.
Are EDSA insiders buying or selling?
Recent insider activity shows net buying of $9.04M.
Continue the stock analysis
Jump to another research area for this company.